Condition : Rheumatoid Arthritis Intervention : Drug: tocilizumab [RoActemra/Actemra] Sponsors : Hoffmann-La Roche; Hoffmann-La Roche Active, not recruiting - verified September 2013

Condition : Arthritis, Rheumatoid Interventions : Drug: BI 695500; Drug: BI 695500; Drug: rituximab; Drug: rituximab; Drug: rituximab Sponsors : Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelh...

This non-interventional study will evaluate the use and efficacy of RoActemra/Actemra (tocilizumab) in patients with moderate to severe rheumatoid arthritis. Eligible patients initiated on RoActemra/A...

This observational multicenter study will evaluate the management of disease and safety in clinical practice in patients with moderate to severe rheumatoid arthritis receiving any biological therapies...

This non-interventional study will evaluate the use and efficacy of RoActemra/Actemra (tocilizumab) in patients with moderate to severe rheumatoid arthritis. Eligible patients initiated on RoActemra/A...

This non-interventional study will evaluate the use and efficacy of RoActemra/Actemra (tocilizumab) in patients with moderate to severe rheumatoid arthritis. Eligible patients initiated on RoActemra/A...

This observational multicenter study will evaluate the management of disease and safety in clinical practice in patients with moderate to severe rheumatoid arthritis receiving any biological therapies...

This observational, multi-center study will evaluate the treatment regimen, treatment responses and safety of RoActemra/Actemra (tocilizumab) therapy in a routine clinical practice in patients with mo...

Condition : Rheumatoid Arthritis Interventions : Drug: tocilizumab [RoActemra/Actemra]; Drug: methotrexate Sponsor : Hoffmann-La Roche Recruiting - verified February 2014

Condition : Rheumatoid Arthritis Interventions : Drug: tocilizumab [RoActemra/Actemra]; Drug: methotrexate Sponsor : Hoffmann-La Roche Recruiting - verified November 2013